Clinic of Internal Medicine, Södra Älvsborgs Hospital, Borås, Sweden.
Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
J Clin Endocrinol Metab. 2019 Nov 1;104(11):5073-5083. doi: 10.1210/jc.2019-00340.
The factors that affect the health-related quality of life (HRQoL) of women with Turner syndrome (TS) are controversial.
The aim was to describe the HRQoL of women with TS with a focus on how given GH treatment and comorbidity influence HRQoL in adulthood and to compare HRQoL of women with TS with that of women in the general population.
Longitudinal cohort study, up to 20 years.
The Turner Center at the Section for Endocrinology and Department of Reproductive Medicine at Sahlgrenska University Hospital, Gothenburg, Sweden.
Women with TS (n = 200), age range 16 to 78 years, were included consecutively and monitored every fifth year between 1995 and 2018. Women from the World Health Organization MONItoring of trends and determinants for CArdiovascular disease project were used as reference populations.
HRQoL was measured using the Psychological General Well-Being index and the Nottingham Health Profile. Associations with somatic variables were assessed using longitudinal linear regression models.
HRQoL was not associated with GH treatment in TS in spite of a mean 5.7 cm taller height. HRQoL was only associated with height per se in one of 13 subscales (P < 0.01). HRQoL was negatively affected by higher age, higher age at diagnosis, and hearing impairment in TS. Women with TS reported a similar HRQoL to the reference population.
No association between previous GH treatment and HRQoL was found during the up to 20 years of follow-up in women with TS. HRQoL of women with TS and the reference population was similar.
影响特纳综合征（TS）女性健康相关生活质量（HRQoL）的因素存在争议。
旨在描述 TS 女性的 HRQoL，重点关注特定 GH 治疗和合并症如何影响成年期的 HRQoL，并比较 TS 女性与普通人群的 HRQoL。
纵向队列研究，最长 20 年。
瑞典哥德堡 Sahlgrenska 大学医院内分泌科特纳中心。
连续纳入了 200 名 TS 女性（年龄 16-78 岁），并在 1995 年至 2018 年间每五年监测一次。使用世界卫生组织 MONItoring 心血管疾病趋势和决定因素项目的女性作为参考人群。
使用心理总体幸福感指数和诺丁汉健康状况问卷评估 HRQoL。使用纵向线性回归模型评估与躯体变量的相关性。
尽管 TS 女性的平均身高增加了 5.7 厘米，但 GH 治疗与 HRQoL 无关。在 13 个子量表中，只有一个子量表（P < 0.01）与身高本身有关。HRQoL 与 TS 中的较高年龄、较年轻时的诊断年龄和听力障碍呈负相关。TS 女性报告的 HRQoL 与参考人群相似。
在 TS 女性长达 20 年的随访中，未发现先前 GH 治疗与 HRQoL 之间存在关联。TS 女性与参考人群的 HRQoL 相似。
Zotero 插件